BACKGROUND:Plasma renin activity (PRA), measured under controlled conditions, is a marker of the degree and persistence of renin-angiotensin system blockade. METHODS: Two similarly designed five-way crossover studies evaluated angiotensin II type 1 (AT1) receptor blockade-induced changes in PRA in quietly seated, ambulatory volunteers who were ingesting uncontrolled diets. At weekly intervals, PRA was measured during the 24 h after administration of placebo, olmesartan medoxomil (20 or 40 mg), or valsartan (80 or 160 mg) (Study CS866-445), or placebo, olmesartan medoxomil (40 mg), valsartan (160 or 320 mg), or irbesartan (300 mg) (Study CS866-448). The primary end point was change in PRA relative to placebo from predose to 24 h postdose (DeltaPRA24). RESULTS: In the 20 subjects who completed each study, there was a direct relationship between baseline PRA and DeltaPRA24 for all doses. Subjects with low PRA (<0.65 ng/mL/h) exhibited very low absolute increases in PRA. The DeltaPRA(24) increased significantly with olmesartan medoxomil 20 mg (P<.01) and 40 mg (P<.001) and valsartan 160 mg (P<.05) but not with valsartan 80 mg. In the second study (in which baseline PRA was lower), DeltaPRA24 increased with olmesartan medoxomil 40 mg (P<.0001), valsartan 320 mg (P<.01), and irbesartan 300 mg (P<.01) but not with valsartan 160 mg. The DeltaPRA24 was greatest with olmesartan medoxomil 40 mg and was dose-related for olmesartan medoxomil but not for valsartan. CONCLUSIONS: The greater DeltaPRA24 with olmesartan medoxomil 40 mg indicates a more prolonged AT1 receptor blockade than with valsartan 80, 160, or 320 mg or irbesartan 300 mg. A routine, clinic ambulatory PRA level can be used as a biochemical marker of the persistence and degree of AT1 receptor blockade in subjects without suppressed PRA levels.
RCT Entities:
BACKGROUND: Plasma renin activity (PRA), measured under controlled conditions, is a marker of the degree and persistence of renin-angiotensin system blockade. METHODS: Two similarly designed five-way crossover studies evaluated angiotensin II type 1 (AT1) receptor blockade-induced changes in PRA in quietly seated, ambulatory volunteers who were ingesting uncontrolled diets. At weekly intervals, PRA was measured during the 24 h after administration of placebo, olmesartan medoxomil (20 or 40 mg), or valsartan (80 or 160 mg) (Study CS866-445), or placebo, olmesartan medoxomil (40 mg), valsartan (160 or 320 mg), or irbesartan (300 mg) (Study CS866-448). The primary end point was change in PRA relative to placebo from predose to 24 h postdose (DeltaPRA24). RESULTS: In the 20 subjects who completed each study, there was a direct relationship between baseline PRA and DeltaPRA24 for all doses. Subjects with low PRA (<0.65 ng/mL/h) exhibited very low absolute increases in PRA. The DeltaPRA(24) increased significantly with olmesartan medoxomil 20 mg (P<.01) and 40 mg (P<.001) and valsartan 160 mg (P<.05) but not with valsartan 80 mg. In the second study (in which baseline PRA was lower), DeltaPRA24 increased with olmesartan medoxomil 40 mg (P<.0001), valsartan 320 mg (P<.01), and irbesartan 300 mg (P<.01) but not with valsartan 160 mg. The DeltaPRA24 was greatest with olmesartan medoxomil 40 mg and was dose-related for olmesartan medoxomil but not for valsartan. CONCLUSIONS: The greater DeltaPRA24 with olmesartan medoxomil 40 mg indicates a more prolonged AT1 receptor blockade than with valsartan 80, 160, or 320 mg or irbesartan 300 mg. A routine, clinic ambulatory PRA level can be used as a biochemical marker of the persistence and degree of AT1 receptor blockade in subjects without suppressed PRA levels.
Authors: Courtney V Brown; Lindsey M Boulet; Tyler D Vermeulen; Scott A Sands; Richard J A Wilson; Najib T Ayas; John S Floras; Glen E Foster Journal: Front Neurosci Date: 2020-04-28 Impact factor: 4.677